A Safety Study of NNZ-2566 in Patients With Rett Syndrome

• ClinicalTrials.gov Identifier: NCT01703533
• Recruitment Status: Completed
• First Posted: October 10, 2012
• Last Update Posted: February 5, 2018
• Sponsor: Neuren Pharmaceuticals Limited
• Collaborators: Baylor College of Medicine; International Rett Syndrome Foundation
• Information provided by (Responsible Party): Neuren Pharmaceuticals Limited

Study Description

Brief Summary:

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.

Condition or disease	Intervention/treatment	Phase
Rett Syndrome	Drug: NNZ-2566; Drug: Placebo	Phase 2

Detailed Description:

Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 67 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
• Study Start Date: March 2013
• Actual Primary Completion Date: September 2014
• Actual Study Completion Date: September 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: NNZ-2566; Glycyl-L-2-Methylpropyl-L-Glutamic Acid	Drug: NNZ-2566; Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Placebo Comparator: Placebo (strawberry flavored solution); Strawberry flavored solution and Water for Injection	Drug: Placebo; Strawberry flavored solution and Water for Injection; Other Name: Strawberry flavored solution 0.5% v/v in Water for Injection

Outcome Measures

Primary Outcome Measures :

1. Adverse events [ Time Frame: Through to Day 40 ]
   Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. SAEs will be examined from randomization through to Day 40. AEs will be examined from dosing through to Day 40.

Secondary Outcome Measures :

1. Change in EEG activity [ Time Frame: Baseline through to Day 40 ]

   Absolute change in the number of spikes in the EEG per hour during the awake state will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).

   Absolute change in the power of frequency bands in the EEG over an hour in the awake state as determined by the Fast Fourier method will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).

   Changes in the frequency of the characteristic repetitive stereotypic hand movements during wakefulness will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).

2. Behavior [ Time Frame: Baseline through to Day 40 ]

   The following measures will be assessed at baseline and Day 26 and the changes compared between active and placebo groups:

   Symptom severity according to the Rett Syndrome Natural History Motor Behavior Assessment (MBA), Clinical Severity Scale (CSS), Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scale (VABS), and Clinical Global Impression of Severity (CGI-S).

   The following assessments will be undertaken at the additional time points specified: CGI-S (screening, baseline, Days 5, 14, 26, and 40), CGI-I (Days 5, 14, 26, and 40), MBA (Baseline, Days 26 and 40), CSS (screening, baseline, Days 26, and 40).

3. Physiological changes [ Time Frame: Baseline through to Day 40 ]
   Changes in autonomic function, i.e. respiratory rhythm, hyperventilation, apneas, oxygen desaturation, and heart rate variation will be calculated between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
4. Global and Functional outcome Measures [ Time Frame: Baseline through to Day 40 ]

   Global outcome as measured by the change in scores on the Rett Syndrome Clinical Severity Score (CSS), The Rett Syndrome Motor-Behavior Assessment Scale (MBA), and the Clinical Global Impression - Severity and Improvement scales (CGI-S and -I) from baseline, during treatment, and post treatment.

   Changes in caregiver assessment of the top three causes for concern as assessed via a Visual Analogue Scale (VAS) will be evaluated for each subject between baseline (pre-treatment), during treatment (Day 26) and after treatment (Day 40).

   Changes in the Aberrant Behavior Checklist (ABC) and Vineland Adaptive Behavior Scales (VABS) will be calculated for each subject between baseline (pre-treatment), and during treatment (Day 26).

Other Outcome Measures:

1. Pharmacokinetics [ Time Frame: Baseline through to Day 40 ]
   The following pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood: Tmax, Cmax (peak), Cmin (trough), CAV at steady state, T1/2 and AUC.

Eligibility Criteria

• Ages Eligible for Study: 16 Years to 45 Years (Child, Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Diagnosis of Rett Syndrome with proven mutation of the MeCP2 gene
• Age 16 to 45 years
• Severity rating of between 10 and 36 (Rett Syndrome Natural History/Clinical Severity Scale)
• Concomitant medications must be stable for >4 weeks prior to enrollment. The following concomitant medications are permitted: anticonvulsants which do not have liver inducing effects; beta-blockers; medications for the treatment of gastroesophageal reflux disease (GERD); medications for the treatment of chronic respiratory conditions such as asthma; medications for the treatment of anxiety, of depression and of psychosis, hormonal contraceptives. Melatonin for difficulties with sleep onset.
• Ability to swallow study medication provided as a liquid solution, or via gastrostomy tube

Exclusion Criteria:

• No detectable abnormality of the EEG during screening period
• Actively undergoing regression
• QTcF exclusions (any of the following): baseline/screening QT/QTcF interval of 450 msec; history of risk factors for torsade de pointes (e.g. heart failure, hypokalemia (serum potassium at screening < 3.0 mmol/L) or family history of long QT syndrome; QT/QTcF prolongation previously or currently controlled with medication
• Current treatment with insulin
• Hgb A1C values outside the normal reference range at screening
• Current or past treatment with IGF-1
• Current or past treatment with growth hormone
• Current treatment with N-methyl-D-aspartate (NMDA) antagonists
• Current or planned use of non-medication based interventional therapy during the period of the study (defined as 4-6 week screening period followed by 4 week dosing and 2 week follow-up period)
• Current clinically significant cardiovascular, renal, hepatic or respiratory disease
• Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the the study medication
• History of, or current cerebrovascular disease or brain trauma
• History of, or current significant endocrine disorder e.g. hypo or hyperthyroidism or diabetes mellitus
• History of, or current malignancy
• Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at screening or baseline
• Confirmed pregnancy
• Significant hearing and/or visual impairment that may affect ability to complete the test procedures
• Enrollment in another clinical trial within the previous 30 days
• Previously randomized in this clinical trial
• Allergy to strawberries

Contacts and Locations

Locations

United States, Alabama

University of Alabama

Birmingham, Alabama, United States, 35294-0113

United States, Minnesota

Gillette Children's Specialty Healthcare

Saint Paul, Minnesota, United States, 55101

United States, Texas

Baylor School of Medicine

Houston, Texas, United States, 77030

Sponsors and Collaborators

Neuren Pharmaceuticals Limited

Baylor College of Medicine

International Rett Syndrome Foundation

Investigators

• Principal Investigator: Daniel G Glaze, M.D.; Baylor College of Medicine
• Principal Investigator: Jeffrey L Neul, M.D., Ph.D.; Baylor College of Medicine
• Principal Investigator: Alan Percy, MD; University of Alabama at Birmingham
• Principal Investigator: Timothy Feyma, MD; Gillette Children's Specialty Healthcare
• Principal Investigator: Arthur Beisang, MD; Gillette Children's Specialty Healthcare

More Information

• Responsible Party: Neuren Pharmaceuticals Limited
• ClinicalTrials.gov Identifier: NCT01703533
• Other Study ID Numbers: Neu-2566-RETT-001
• First Posted: October 10, 2012
• Last Update Posted: February 5, 2018
• Last Verified: January 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Neuren Pharmaceuticals Limited:

Autism; Rett's Syndrome; Rett Disorder; Rett's Disorder; Ataxia

Additional relevant MeSH terms:

Rett Syndrome; Syndrome; Disease; Pathologic Processes; Mental Retardation, X-Linked; Intellectual Disability; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System